| Not Yet Recruiting | An Ultra-short Course of Primaquine for the Radical Cure of Vivax Malaria NCT07468526 | Menzies School of Health Research | Phase 3 |
| Not Yet Recruiting | A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults NCT07470424 | University of Oxford | Phase 1 |
| Not Yet Recruiting | Intermittent Preventive Treatment of Malaria in School-age Children to Decrease Community Transmission NCT07246525 | University of California, San Francisco | Phase 4 |
| Suspended | Safety Evaluation of PfSPZ Vaccine in Pregnant Women in Mali (MalVIP1) NCT05652504 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Not Yet Recruiting | R21/MM Dosing, Presentations, and Preservatives NCT07194668 | University of Oxford | Phase 4 |
| Not Yet Recruiting | This is a Clinical Study to Assess Whether the Combination of SJ733 and Tafenoquine Will be a Safe and Rapidly NCT07430592 | R. Kiplin Guy | Phase 2 |
| Withdrawn | L9LS-R21 Interaction NCT07208760 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Not Yet Recruiting | Long-acting Spatial Emanators / Repellents (LASER) NCT07387341 | Liverpool School of Tropical Medicine | N/A |
| Recruiting | Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective NCT07358910 | Institut Pasteur du Cambodge | — |
| Recruiting | OPTImizing Malaria And HIV Treatment in a Shifting Landscape in Africa NCT06967519 | Yale University | Phase 4 |
| Recruiting | Effectiveness of Malaria Vaccines in Reducing the Risk of Invasive Non-typhoidal Salmonella Disease NCT07416461 | International Vaccine Institute | — |
| Recruiting | A Study to Assess the Safety and Immunogenicity of a Vaccine Against Malaria in Healthy Children Aged 5-60 Mon NCT07036159 | GlaxoSmithKline | Phase 2 |
| Active Not Recruiting | First-in-Human PfSPZ-LARC2 Vaccination/CHMI NCT06735209 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | L9LS in Women of Childbearing Potential in Mali NCT07060508 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Not Yet Recruiting | Comparing Safety and Protective Efficacy of Vaccine Candidate PfSPZ-CVac and MVA ME-TRAP/ ChAd63 ME-TRAP in Ad NCT05441410 | University Hospital Tuebingen | Phase 1 / Phase 2 |
| Recruiting | Monoclonal Antibodies in Children With Severe Anaemia or Severe Malaria to Prevent Malaria After Hospital Disc NCT07082205 | Liverpool School of Tropical Medicine | Phase 3 |
| Withdrawn | MaCRA Part B in Nigeria NCT06805110 | PATH | N/A |
| Withdrawn | MaCRA Part B in Côte d'Ivoire NCT06804902 | PATH | N/A |
| Recruiting | A Study of Oral E1018 in Healthy Adult Participants NCT06854042 | Eisai Inc. | Phase 1 |
| Completed | Vivax Elimination With Tafenoquine (VET) Study NCT06575647 | Shoklo Malaria Research Unit | Phase 4 |
| Not Yet Recruiting | Host Immunity, Plasmodium and Pathogens Co-Infections NCT06769815 | Institut Pasteur | N/A |
| Completed | Knowledge and Attitude Among Healthcare Workers Towards Malaria Vaccine, Sudan 2025. NCT07194499 | Research and Publication office | — |
| Recruiting | Induced Blood-Stage Malaria in Healthy Malaria-Naive Adults to Assess the Safety and Infectivity of Plasmodium NCT06607003 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | FocaL Mass Drug Administration for Vivax Malaria Elimination NCT05690841 | University of California, San Francisco | Phase 3 |
| Recruiting | Evaluation of Artesunate in Infants Being Treated for Severe Malaria NCT06555809 | Amivas Inc. | — |
| Active Not Recruiting | Targeted Antimalarial Drug Administration for Seasonal Migrant Populations in Amhara Region, Ethiopia NCT06516042 | PATH | Phase 3 |
| Active Not Recruiting | L9LS MAb in Malian Infants NCT06461026 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Recruiting | Pregnancy Registry in Mali NCT06468319 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Parasite Clearance and Protection From Infection (PCPI) in Zambia NCT06166498 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Parasite Clearance and Protection From Infection (PCPI) in Cameroon NCT06173206 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Recruiting | Evaluation of the Protective Efficacy of a Spatial Repellent to Reduce Malaria Prevalence in Uganda NCT06232954 | Africa Power Limited | N/A |
| Recruiting | Seasonal R21 Mass Vaccination for Malaria Elimination NCT06578572 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Unknown | Effectiveness and Cost-effectiveness of Integrated Model for Malaria and Helminth Control NCT06182176 | London School of Hygiene and Tropical Medicine | N/A |
| Withdrawn | Spatial Repellents for Malaria Control NCT06122142 | University of Notre Dame | N/A |
| Active Not Recruiting | Open-Label Study to Assess Meplazumab in Adult Patients Diagnosed with Plasmodium Falciparum NCT06040346 | Jiangsu Pacific Meinuoke Bio Pharmaceutical Co Ltd | Phase 2 |
| Completed | A Study to Evaluate Antimalarial Activity and Safety of MK-7602 in Healthy Adults (MK-7602-003) NCT06294912 | Merck Sharp & Dohme LLC | Phase 1 |
| Recruiting | Malaria Molecular Surveillance in Mozambique (Phase 2) NCT06529237 | Centro de Investigacao em Saude de Manhica | — |
| Completed | Improving Knowledge, Attitudes and Practices for Malaria Prevention in the Embera Katio Population NCT06590597 | Universidad de Antioquia | N/A |
| Active Not Recruiting | Evaluation of a Comprehensive School Health Programme in Zambia NCT06560853 | London School of Economics and Political Science | N/A |
| Suspended | Evaluation of Vector and Chemoprevention-based Interventions to Reduce Malaria Burden in Urban Daaras of Touba NCT06225297 | PATH | Phase 4 |
| Recruiting | L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) NCT05934318 | Liverpool School of Tropical Medicine | N/A |
| Unknown | Buikwe Electronic Community Health Information System Impact Study NCT06318078 | Malaria Consortium | N/A |
| Completed | LLIN Evaluation in Uganda Project (LLINEUP3) NCT05950191 | University of California, San Francisco | N/A |
| Completed | A Clinical Trial to Evaluate the Safety, Efficacy and Immune Responses After Vaccination With an Investigation NCT06069544 | BioNTech SE | Phase 1 / Phase 2 |
| Active Not Recruiting | Net Transition Initiative: Efficacy of Two Next-generation Nets for Control of Malaria in Cote d'Ivoire NCT05796193 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon NCT06278181 | Karolinska Institutet | — |
| Completed | Pan-Malaria Transmission-Blocking Vaccine AnAPN1 NCT05905432 | Centre de Recherche Médicale de Lambaréné | Phase 1 |
| Completed | Assessment of the Malaria Vaccine Candidate SumayaVac-1 in Healthy Adults Aged 18-45 Years Living in a Malaria NCT05644067 | Swiss Tropical & Public Health Institute | Phase 1 |
| Active Not Recruiting | A Study to Assess the Safety and Effectiveness of Two Experimental Malaria Vaccines NCT05978037 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability, Pharmacokinetics and Protective Efficacy of MAM01 in Healthy Adults NCT05891236 | Gates Medical Research Institute | Phase 1 |
| Completed | Piperaquine Granule Formulation Relative Bioavailability and Food Effect Study in Healthy Volunteers. NCT05930782 | Medicines for Malaria Venture | Phase 1 |
| Active Not Recruiting | Perennial Malaria Chemoprevention (PMC) in Côte D'Ivoire NCT05856357 | London School of Hygiene and Tropical Medicine | — |
| Active Not Recruiting | Perennial Malaria Chemoprevention (PMC) Effect Study NCT06155448 | Malaria Consortium | N/A |
| Completed | Study of the Plasmodium Vivax Transmission-blocking Vaccine Pvs230D1-EPA/Matrix-M to Assess Safety, Immunogeni NCT05913973 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falci NCT05979207 | Medicines for Malaria Venture | Phase 1 |
| Unknown | Chemoprevention Efficacy Study Nigeria NCT05979896 | Malaria Consortium | Phase 4 |
| Active Not Recruiting | Perennial Malaria Chemoprevention (PMC) in Cameroon NCT05889052 | London School of Hygiene and Tropical Medicine | — |
| Completed | CHILD (Child Health and Infection With Low Density) Malaria NCT05567016 | University of California, San Francisco | N/A |
| Unknown | Innovative Intermittent Preventive Treatment Approaches to Reduce Malaria Burden in School-age Children in Bur NCT05946642 | Malaria Consortium | Phase 3 |
| Completed | Understanding and Maximizing the Community Impact of Antimalarial Treatment (INDIE-SMC) NCT05878366 | London School of Hygiene and Tropical Medicine | N/A |
| Withdrawn | Use of Malaria Rapid Diagnostic Tests as a Decision Aid for the Management of Fever by International Travelers NCT02900079 | Institute of Tropical Medicine, Belgium | — |
| Recruiting | ACT vs CQ With Tafenoquine for P. Vivax Mono-infection NCT05788094 | Shoklo Malaria Research Unit | Phase 4 |
| Active Not Recruiting | A Study to Compare Two Dosing Regimens for a New Malaria Vaccine NCT06141057 | University of Oxford | Phase 1 |
| Completed | Field Evaluations of Innovative Tools for Vector-borne Disease Control in Conflict-affected Communities NCT06179732 | The Mentor Initiative | Phase 3 |
| Completed | Impact of Differential and Systematic Diagnosis of Dengue, Chikungunya and Malaria on Patient Management and A NCT06257810 | BioMérieux | N/A |
| Completed | L9LS MAb in Malian Adults NCT05816330 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Comparative Study of Thrombocytopenia in Plasmodium Vivax and Falciparum Malaria NCT07122232 | Rafiullah Hotak | — |
| Active Not Recruiting | EaveTubes for Vector Control NCT05736679 | University of Notre Dame | N/A |
| Completed | Clinical Validation of Novel Malaria Diagnostic Tools for POC Point-of-Care Testing NCT06225700 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Efficacy of Only IV Artesunate Versus IV Artesunate Plus IV Quinine in the Treatment of Severe Malaria in Chil NCT06472258 | RESnTEC, Institute of Research | N/A |
| Completed | Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIV NCT05385510 | University of Oxford | Phase 1 |
| Completed | Therapeutic Efficacy of Chloroquine Plus Primaquine in the Treatment of Uncomplicated Plasmodium Vivax NCT06044805 | Dinka Dugassa | Phase 4 |
| Completed | Safety and Immune Responses After Vaccination With an Investigational RNA-based Vaccine Against Malaria NCT05581641 | BioNTech SE | Phase 1 |
| Terminated | A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Hete NCT05604521 | Sanaria Inc. | Phase 1 |
| Terminated | A Study of the Plasmodium Falciparum Malaria Vaccine Candidate Pfs48/45 in Matrix-M Adjuvant in the UK NCT05400746 | University of Oxford | EARLY_Phase 1 |
| Unknown | Africa Ready Malaria Screening NCT06153862 | University of Ghana | N/A |
| Completed | Anti-malaria MAb in Kenyan Children NCT05400655 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Active Not Recruiting | Sulfadoxine-pyrimethamine Plus Dihydroartemisinin-piperaquine for Intermittent Preventive Treatment in Pregnan NCT05426434 | Menzies School of Health Research | Phase 3 |
| Completed | Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria NCT06300970 | Centers for Disease Control and Prevention | Phase 4 |
| Unknown | Ivermectin-artemisinin Combination Therapy for Eradication of Malaria NCT05605925 | Makerere University | Phase 4 |
| Active Not Recruiting | Trajectories and Mechanisms of Recovery From Malaria: An Observational Study NCT05149157 | Imperial College London | — |
| Unknown | Effectiveness, Feasibility and Acceptability of Seasonal Malaria Chemoprevention in Aweil South County in Sout NCT05471544 | Malaria Consortium | Phase 3 |
| Completed | A Study of Blood-stage Controlled Human Plasmodium Falciparum Malaria Infection in Tanzania NCT04788862 | University of Oxford | N/A |
| Unknown | Chemoprevention Efficacy Study in Burkina Faso NCT05478954 | Malaria Consortium | Phase 4 |
| Unknown | Evaluating the Clinical Performance and Usability of Novel Malaria RDTs in Brazil NCT05317117 | PATH | N/A |
| Completed | Health Education by Buddhist Monks to Promote Malaria Knowledge and Preventive Practices in Rural Myanmar NCT06386367 | Myanmar Health Network Organization | N/A |
| Completed | Abbott NxTekTM Malaria RDT WHO Prequalification Study NCT05444790 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Unknown | Feasibility and Safety of Combining Anti-malarial With Deworming Drugs in African Children NCT05354258 | London School of Hygiene and Tropical Medicine | N/A |
| Recruiting | Observational Study of the Safety of Intravenous Artesunate Treatment of Pregnant Women and Their Infants NCT05285735 | Amivas Inc. | — |
| Completed | Permethrin-treated Baby-wraps for the Prevention of Malaria in Children NCT05391230 | University of North Carolina, Chapel Hill | N/A |
| Unknown | Effectiveness and Chemoprevention Efficacy of Implementing Seasonal Malaria Chemoprevention in Karamoja Region NCT05323721 | Malaria Consortium | Phase 4 |
| Completed | Performance Evaluation of Malaria Plus Rapid Diagnostic Tests (RDTs) for the Detection of Plasmodium Infection NCT05286359 | Abbott Rapid Dx | N/A |
| Completed | Assessment of Safety and Immunogenicity of a Single Vial Presentation of R21/Matrix-M and Co-Administration Wi NCT05155579 | University of Oxford | Phase 1 |
| Completed | Safety, Tolerability, Immunogenicity and Protective Efficacy of PfSPZ Vaccine and PfSPZ-CVac in Indonesian Adu NCT03503058 | Sanaria Inc. | Phase 2 |
| Unknown | Plasmodium Vivax Among Duffy Negative Population in Cameroon. NCT05058885 | University of Dschang | — |
| Unknown | ERASE - Impact of COVID-19 on Malaria Control NCT05348746 | Doctors with Africa - CUAMM | — |
| Completed | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz NCT05330273 | Novartis Pharmaceuticals | Phase 1 |
| Unknown | Efficacy and Safety of Artemether-Lumefantrine and Dihydroartemisinin-Piperaquine in Cameroon NCT05340153 | University of Yaounde 1 | Phase 4 |
| Completed | Pyronaridine in Healthy Adult Participants Infected With Blood Stage Malaria NCT05287893 | Medicines for Malaria Venture | Phase 1 |
| Completed | PfSPZ Vaccine Trial in Malian Children NCT04940130 | Sanaria Inc. | Phase 2 |
| Completed | MMV533 Plasmodium Falciparum Volunteer Infection Study NCT05205941 | Medicines for Malaria Venture | Phase 1 |
| Completed | Anti-malaria MAb in Malian Children NCT05304611 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Completed | Broad One Health Endectocide-based Malaria Intervention in Africa (BOHEMIA) NCT04966702 | Barcelona Institute for Global Health | Phase 3 |
| Completed | In Vivo Efficacy of Artemether-Lumefantrine, Amodiaquine-Artesunate, Dihydroartemisinin-Piperaquine, and Piron NCT05343312 | Centro de Investigacao em Saude de Manhica | Phase 4 |
| Completed | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Met NCT05236530 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Community Dynamics of Malaria Transmission in Humans and Mosquitoes at Maferinyah Sub-Prefecture, Guinea NCT04969913 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Evaluating ATSBs for Malaria Reduction in Kenya NCT05219565 | Liverpool School of Tropical Medicine | N/A |
| Completed | Blood-Stage Plasmodium Vivax Cell Bank NCT05095272 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | MULTIple Doses of IPTi Proposal: a Lifesaving High Yield Intervention NCT05085340 | Barcelona Institute for Global Health | — |
| Active Not Recruiting | Modifying Immunity in Children With DihydROartemisinin-Piperaquine (MIC-DroP) NCT04978272 | Grant Dorsey, M.D, Ph.D. | Phase 3 |
| Unknown | Effectiveness of Seasonal Malaria Chemoprevention in Nampula Province, Mozambique: Type Two Hybrid Implementat NCT05186363 | Malaria Consortium | Phase 4 |
| Recruiting | Star Homes Project 2 NCT04529434 | University of Oxford | N/A |
| Completed | RapiGEN BIOCREDIT Malaria Ag RDTs WHO Prequalification Study NCT05085301 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Unknown | Malaria Control : Improving Access to Prevention, Diagnostic and Care for Vulnerable Rural Communities NCT05535465 | Institut de Recherche pour le Developpement | N/A |
| Completed | Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Itraconazole NCT05084651 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Monitoring Pregnant Women for Antimalarial Drug Resistance NCT05072613 | University of Oxford | — |
| Completed | Short Course Radical Cure of P. Vivax Malaria in Nepal NCT04079621 | Menzies School of Health Research | Phase 4 |
| Recruiting | Strengthening the Evidence for Policy on the RTS,S/AS01 Malaria Vaccine NCT05041556 | Kintampo Health Research Centre, Ghana | — |
| Completed | Plasmodium Falciparum Genomic Intelligence in Mozambique NCT05306067 | Centro de Investigacao em Saude de Manhica | — |
| Active Not Recruiting | Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District NCT04704674 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults NCT04966871 | Sanaria Inc. | Phase 1 |
| Completed | Trial to Evaluate L9LS in Healthy Adults NCT05019729 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Study Of Zy-19489 Administered Via Oral Route To Investigate The Safety, Tolerability And Pharmacokinetics I NCT05206201 | Zydus Lifesciences Limited | Phase 1 |
| Suspended | Baromètre Santé Adulte 2021-2022 NCT05218304 | Agence Sanitaire et Sociale de Nouvelle Calédonie | N/A |
| Completed | Spatial Repellents for Vector Control NCT04795648 | University of Notre Dame | N/A |
| Completed | Boosting the Impact of SMC Through Simultaneous Screening and Treatment of Roommates NCT04816461 | Institut de Recherche en Sciences de la Sante, Burkina Faso | Phase 4 |
| Completed | Impact of Malaria Mass Drug Administration on Malaria Prevalence in Under 15 Children and Pregnant Women NCT07358767 | Noguchi Memorial Institute for Medical Research | N/A |
| Completed | Molecular Basis of Erythrocyte Invasion by Plasmodium Vivax Into Duffy-Negative Erythrocytes in Mali NCT03304691 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Mass Drug Administration of Dihydroartemisinin-piperaquine + Single Low-dose Primaquine to Accelerate Toward E NCT04864444 | University of California, San Francisco | N/A |
| Completed | LAMP Detection of Malaria in PREGnancy (LAMPREG) Trial NCT03754322 | University of Calgary | N/A |
| Completed | Malaria Transmission in Humans and Mosquitoes at the Area of Sabou, Burkina Faso NCT04650815 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety and Efficacy of Maytenus Senegalensis for the Treatment of Uncomplicated Malaria NCT04944966 | Ifakara Health Institute | Phase 2 |
| Unknown | Evaluation of Three Artemisinin-based Combinations for the Treatment of Uncomplicated Malaria in Childreen in NCT04778813 | Centre national de recherche et de formation sur le paludisme | Phase 4 |
| Unknown | Performance Evaluation of Malaria Plus RDTs NCT03960632 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Safety and Efficacy of R0.6C Vaccine NCT04862416 | Radboud University Medical Center | Phase 1 |
| Unknown | Validation of a CDSA Strategy to Reduce Antibiotic Prescription in Senegal NCT05050825 | Foundation for Innovative New Diagnostics, Switzerland | N/A |
| Active Not Recruiting | R21/Matrix-M in African Children Against Clinical Malaria NCT04704830 | University of Oxford | Phase 3 |
| Active Not Recruiting | Evaluation of IR3535 as a Spatial Repellent for Malaria Control. NCT04419766 | Universidade Nova de Lisboa | N/A |
| Completed | Proactive Community Case Management for Malaria in Zambia NCT04839900 | PATH | N/A |
| Completed | Dihydroartemisinin-Piperaquine or Sulphadoxine-Pyrimethamine for the Chemoprevention of Malaria in Sickle Cell NCT04844099 | Liverpool School of Tropical Medicine | Phase 3 |
| Completed | Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Ni NCT04428385 | Duke University | N/A |
| Completed | Clinical Investigation Study to Evaluate the Consistency and Reproducibility of Two Consecutive Mosquito Feedi NCT04666350 | PATH | — |
| Completed | Spatial Repellents for the Prevention of Malaria in Kenya NCT04766879 | University of Notre Dame | N/A |
| Completed | Safety and Efficacy of CIS43LS Anti-malaria mAb in Mali NCT04329104 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Infection Tracking in Travellers. The Project Aims to Identify Profiles of Travel-associated Illness and to Fo NCT04672577 | Patricia Schlagenhauf | — |
| Unknown | Uganda Housing Modification Study NCT04622241 | Infectious Diseases Research Collaboration, Uganda | N/A |
| Unknown | Household-level Impact of IPT of Malaria in Schoolchildren NCT04660110 | Makerere University | Phase 3 |
| Completed | Characterizing Humoral Immune Response to Mosquito Bites NCT04478370 | University of Oxford | N/A |
| Unknown | Optimizing Malaria Treatment for HIV-Malaria Co-infected Individuals NCT04708496 | Makerere University | Phase 4 |
| Unknown | Mobile Point of Care Diagnostic Testing for Ebola Virus Disease in DRC NCT04235361 | University of Stirling | — |
| Completed | Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: TESTsmART Aim 2 - Ke NCT04428307 | Duke University | N/A |
| Completed | Malaria as a Risk Factor for COVID-19 in Western Kenya and Burkina Faso NCT04695197 | Liverpool School of Tropical Medicine | Phase 3 |
| Completed | An MRI Ancillary Study of a Malaria Fever Investigation NCT05746819 | University of Rochester | — |
| Unknown | Effectiveness of a Community-delivered Integrated Malaria Elimination (CIME) Model in Myanmar NCT04695886 | Macfarlane Burnet Institute for Medical Research and Public Health Ltd | N/A |
| Completed | Optimal Chemopreventive Regimens to Prevent Malaria and Improve Birth Outcomes in Uganda NCT04336189 | Grant Dorsey, M.D, Ph.D. | Phase 3 |
| Completed | Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Ne NCT04724161 | PATH | — |
| Unknown | Attractive Targeted Sugar Bait Phase III Trial in Zambia NCT04800055 | PATH | N/A |
| Completed | Safety and Efficacy of Recommended Antimalarial in the Democratic Republic of the Congo NCT04618523 | Ministry of Public Health, Democratic Republic of the Congo | Phase 4 |
| Completed | LLIN Evaluation in Uganda Project NCT04566510 | University of California, San Francisco | N/A |
| Completed | Innovation Platform NCT04558528 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Completed | Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Ne NCT04545905 | PATH | — |
| Completed | Assess Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Profile of Ruxolitinib With Artemether-lumefa NCT04456634 | Medicines for Malaria Venture | Phase 1 |
| Completed | Baseline Cohort Malaria Morbidity Study NCT04601714 | Groupe de Recherche Action en Sante | — |
| Completed | Perceptions, Representations and Experiences of Malaria Prophylaxis in Patients Born in Endemic Areas and Livi NCT04494854 | Centre Hospitalier Intercommunal Creteil | — |
| Completed | Efficacy of Antimalarial Drugs Used for the Treatment of Uncomplicated Malaria, Plasmodium Falciparum, at the NCT05070520 | Programme National de Lutte contre le Paludisme, Niger | Phase 4 |
| Completed | Gut and Azithromycin Mechanisms in Infants and Children II NCT04315272 | University of California, San Francisco | Phase 4 |
| Completed | Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generate NCT04716387 | PATH | — |
| Completed | A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of a Single Doses of MMV533. NCT04323306 | Medicines for Malaria Venture | Phase 1 |
| Completed | Study to Assess Safety, Tolerability and Phamacokinetics of KAE609 Administered Intravenously in Healthy Subje NCT04321252 | Novartis Pharmaceuticals | Phase 1 |
| Completed | Evaluation of the Implementation and Effectiveness of Intermittent Preventive Treatment for Malaria Using Dihy NCT04245033 | National Institute for Medical Research, Tanzania | Phase 4 |
| Unknown | Assessment of a Combined Strategy of SMC + Nutrients Supplementation to Tackle Malaria and Malnutrition NCT04238845 | Institut de Recherche en Sciences de la Sante, Burkina Faso | N/A |
| Completed | Malaria Prevalence Around Maferinyah, Guinea NCT04105855 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Dihydroartemisinin-piperaquine for Seasonal Malaria Chemoprophylaxis in Tanzania NCT05874869 | Richard Mwaiswelo | N/A |
| Completed | Efficacy of Two Dual Active Ingredient Long Lasting Insecticidal Nets for Control of Malaria Transmitted by Py NCT03931473 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Study to Assess Efficacy of Artemether-lumefantrine Prophylaxis Against Forest Malaria in Cambodia (PAL_Cambod NCT04041973 | University of Oxford | N/A |
| Completed | Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generate NCT04230161 | PATH | — |
| Completed | Automated Microscopy Evaluation Study NCT04558515 | Foundation for Innovative New Diagnostics, Switzerland | — |
| Unknown | Evaluation of Targeted Mass Drug Administration for Malaria in Ethiopia NCT04241705 | Armauer Hansen Research Institute, Ethiopia | N/A |
| Completed | Trial to Evaluate CIS43LS in Healthy Adults NCT04206332 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Biomarkers of P. Vivax Relapse NCT04228315 | Armed Forces Research Institute of Medical Sciences, Thailand | N/A |
| Terminated | Assessing the Impact of Group Antenatal Care on IPTp Uptake in Tanzania NCT04148690 | Centers for Disease Control and Prevention | N/A |
| Completed | Malaria High-Risk Populations in Namibia NCT04094727 | University of California, San Francisco | Phase 4 |
| Completed | Getting Malaria "Off the Back" of Women and Children in Western Uganda NCT04102592 | University of North Carolina, Chapel Hill | N/A |
| Completed | Plasmodium and Other Parasites in Pregnant Women and Children Around Margibi and Montserrado Counties, Liberia NCT03719599 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Recruiting | Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants NCT03937817 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Improving Maternal heAlth by Reducing Malaria in African HIV Women NCT03671109 | Barcelona Institute for Global Health | Phase 3 |
| Withdrawn | A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrou NCT04020653 | Neopharma Japan Co., Ltd. | Phase 2 |
| Completed | Optimizing Benefits While Reducing Risks of Iron in Malaria-endemic Areas NCT03897673 | University of Minnesota | N/A |
| Completed | Reducing the Risk of P. Vivax After Falciparum Infections in Co-endemic Areas NCT03916003 | Menzies School of Health Research | Phase 4 |
| Unknown | P. Falciparum Infection Dynamics and Transmission to Inform Elimination NCT04053907 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Effectiveness of Malaria Camps as Part of the Odisha State Malaria Elimination Drive NCT03963869 | NYU Langone Health | N/A |
| Completed | Repeat Ivermectin Mass Drug Administrations for MALaria Control II NCT03967054 | Brian Foy | Phase 3 |
| Completed | Estimating the Malaria Prevention Impact of New Nets: Observational Analyses to Evaluate the Evidence Generate NCT04157894 | PATH | — |
| Completed | Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites NCT03989102 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Active Not Recruiting | Efficacy of Focal Primaquine Mass Administration for Eliminating Plasmodium Vivax Malaria in Northern Myanmar NCT06392152 | Pyae Linn Aung | N/A |
| Completed | VAC 072-An Efficacy Study of R21/MM in Different Dose Schedules NCT03970993 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Single Low-dose Primaquine Efficacy and Safety. NCT03352843 | Tropical Pesticides Research Institute, Tanzania | Phase 4 |
| Completed | Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): NCT03952650 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 / Phase 2 |
| Completed | Pfs230D1M-EPA/AS01 Vaccine, a Transmission Blocking Vaccine Against Plasmodium Falciparum, in an Age De-Escala NCT03917654 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 2 |
| Unknown | Infections in Migrants in Sweden - the Importance of Malaria and Other Parasitic Infections NCT05086887 | Region Stockholm | — |
| Unknown | Malaria Birth Cohort (MBC) in Agogo, Ghana NCT04050566 | Bernhard Nocht Institute for Tropical Medicine | — |
| Completed | Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ) NCT04002687 | Medicines for Malaria Venture | Phase 1 |
| Completed | Malaria Diagnostic Testing and Conditional Subsidies to Target ACTs in the Retail Sector: the TESTsmART Trial NCT03810014 | Duke University | N/A |
| Completed | A Study Assessing the Safety, Efficacy, and Impact of GlaxoSmithKline Biologicals' RTS, S/AS01E Malaria Vaccin NCT03855995 | GlaxoSmithKline | — |
| Completed | Diagnostic and Prognostic Biomarkers for Childhood Bacterial Pneumonia NCT03996967 | Boston University | — |
| Completed | A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Bo NCT03824236 | GlaxoSmithKline | Phase 2 |
| Completed | Efficacy of Three Novel Bi-treated Long Lasting Insecticidal Nets NCT03554616 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Combination Momordica Charantia Extract and Primaquine Againts Plasmodium Falciparum Uncomplicated and Plasmod NCT06036030 | Syamsudin Abdillah,Ph.D, Pharm D | Phase 2 |
| Completed | Aggressive Antipyretics for Fever Reduction in CNS Malaria NCT03399318 | University of Rochester | Phase 2 |
| Completed | Study to Assess the Vaccine Efficacy Against Malaria Infection, in Children Immunized With the Primary and Yea NCT03281291 | GlaxoSmithKline | — |
| Completed | Safety, Tolerability and Chemoprotective Activity of P218 in PfSPZ Challenge Model NCT03707041 | Medicines for Malaria Venture | Phase 1 |
| Completed | Feasibility, Acceptability and Costs of a Multiple First-lines Artemisinin-based Combination Therapies NCT04265573 | Groupe de Recherche Action en Sante | — |
| Completed | VAC063C: A Study to Assess Repeat Blood-stage P. Falciparum Infection NCT03906474 | University of Oxford | N/A |
| Completed | An Efficacy Study of IV Boosting With ChAd63/MVA ME-TRAP NCT03707353 | University of Oxford | Phase 1 / Phase 2 |
| Withdrawn | Chloroquine (CQ) and Azithromycin (AZ) Combination for Malaria Prophylaxis NCT03278808 | U.S. Army Medical Research and Development Command | Phase 2 |
| Completed | Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Malaria Infection in Malaria Naïve Adults NCT03341754 | U.S. Army Medical Research and Development Command | Phase 1 |
| Completed | Defining Skin Immunity of a Bite of Key Insect Vectors in Humans NCT03641339 | National Institute of Allergy and Infectious Diseases (NIAID) | N/A |
| Unknown | Monthly Versus Two Doses of Ante-Natal Intermittent Preventive Treatment With Sulphadoxine-Pyrimethamine NCT03599596 | University College Hospital, Ibadan | Phase 1 |
| Withdrawn | Dried Leaf Artemisia (DLA) Compared to Artemisinin Combination Therapy (ACT) vs Malaria NCT03199755 | Worcester Polytechnic Institute | Phase 2 |
| Completed | Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers Receiving a Seven Day Dose Regim NCT03934450 | University of Mississippi, Oxford | Phase 1 |
| Completed | Mass Drug Administration of Ivermectin and Dihydroartemisinin-piperaquine as an Additional Intervention for Ma NCT03576313 | London School of Hygiene and Tropical Medicine | Phase 3 |
| Completed | Study Assessing Pharmacokinetics and Bioavailability of Three Novel Triazine Compounds NCT03436160 | U.S. Army Medical Research and Development Command | EARLY_Phase 1 |
| Completed | P. Falciparum Infection Dynamics and Transmission to Inform Elimination (INDIE-1a) NCT03705624 | London School of Hygiene and Tropical Medicine | N/A |
| Unknown | Malaria in Strasbourg University Hospital NCT03594084 | University Hospital, Strasbourg, France | — |
| Terminated | Safety and Pharmacokinetics Study of DM1157 to Treat Malaria NCT03490162 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Regimen Optimization Trial of PfSPZ Vaccine in Equatorial Guinea NCT03590340 | Sanaria Inc. | Phase 1 |
| Completed | Dynamics of Subclinical Malaria: Preliminary Study NCT03483571 | Duke University | — |
| Completed | Evaluation of a Digital Microscope for Malaria NCT03512678 | University of Oxford | — |
| Completed | Community Access to Rectal Artesunate for Malaria NCT03568344 | Swiss Tropical & Public Health Institute | — |
| Completed | Safety, Tolerability and Protective Efficacy of PfSPZ Vaccine in Gabonese Children NCT03521973 | Sanaria Inc. | Phase 2 |
| Completed | Monitoring of Perfusion in Sepsis and Malaria NCT03641534 | University of Oxford | — |
| Completed | Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NCT03510481 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Unknown | Liberia National Community Health Assistant (NCHA) Program and Under-five Mortality NCT05123378 | Last Mile Health | N/A |
| Completed | Safety, Tolerability and Antimalarial Activity of Single Doses of OZ439 and PQP NCT03542149 | Medicines for Malaria Venture | Phase 1 |
| Completed | Evaluation of a New Malaria Control Strategy Amongst Gold Miners Working Illegally in French Guiana (Malakit) NCT03695770 | Centre Hospitalier de Cayenne | N/A |
| Unknown | Transmission Dynamics of Residual and Re-emerging Malaria in the Amazon: Defining a Roadmap to Malaria Elimina NCT03689036 | Oswaldo Cruz Foundation | — |
| Completed | Improving PRegnancy Outcomes With Intermittent preVEntive Treatment in Africa NCT03208179 | Liverpool School of Tropical Medicine | Phase 3 |
| Completed | Susceptibility of Gambian Adults to PfSPZ-Challenge Infection in the Controlled Human Malaria Infection Model NCT03496454 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children (MEFI_III) NCT04370977 | Centro de Investigacao em Saude de Manhica | Phase 4 |
| Completed | Study to Evaluate Safety, Immunogenicity and Efficacy of PfSPZ Vaccine in HIV Negative and HIV Positive Tanzan NCT03420053 | Sanaria Inc. | Phase 1 |
| Completed | Community Dynamics of Malaria Transmission and Mosquito Feeding in Bancoumana, Mali NCT03304704 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Preventing Mental Health Problems After Childhood Severe Malaria NCT03432039 | Makerere University | N/A |
| Completed | Safety of KAE609 in Adults With Uncomplicated Plasmodium Falciparum Malaria. NCT03334747 | Novartis Pharmaceuticals | Phase 2 |
| Unknown | Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents for Malaria Prevention NCT02938975 | Ifakara Health Institute | Phase 3 |
| Terminated | MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria NCT02880241 | Medicines for Malaria Venture | Phase 2 |
| Completed | Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating NCT03276962 | GlaxoSmithKline | Phase 2 |
| Completed | Prevalence Survey of Antimalarial Drug Resistance Markers NCT03217851 | University of Oxford | — |
| Completed | Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas NCT03128515 | Indiana University | Phase 3 |
| Completed | A Safety and Efficacy Study of ChAdOx1 LS2 and MVA LS2 NCT03203421 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Impact of Scaling up Mass Testing, Treatment and Tracking on Malaria Prevalence Among Children NCT04167566 | Noguchi Memorial Institute for Medical Research | N/A |
| Completed | Dose Escalation PfSPZ-CVac NCT03083847 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | Efficacy, Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Evaluating Different D NCT03162614 | GlaxoSmithKline | Phase 2 |
| Completed | Safety and Protective Efficacy of Genetically Attenuated PfSPZ-GA1 Vaccine in Healthy Dutch Volunteers NCT03163121 | Sanaria Inc. | Phase 1 |
| Completed | Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of NCT02699099 | GlaxoSmithKline | Phase 3 |
| Completed | Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1 NCT02898779 | University of Mississippi, Oxford | Phase 1 |
| Completed | A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administr NCT03084289 | University of Oxford | Phase 1 |
| Completed | Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo NCT02940756 | Ministry of Public Health, Democratic Republic of the Congo | Phase 4 |
| Completed | Absolute BA and OZ439 PK Effect of Different OZ439 Dose Volumes and Cobicistat Co-administration Study NCT04069221 | Medicines for Malaria Venture | Phase 1 |
| Completed | Impact of Malaria on Pregnant Women in Ouelessebougou, Mali NCT02974608 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Unknown | Mobilization at the Level of Schools on the Behavioral Change in Favor of the Fight Against Malaria in Mbandjo NCT04570241 | Cameroon Coalition Against Malaria (CCAM) | N/A |
| Completed | Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi NCT03009526 | Kamuzu University of Health Sciences | Phase 3 |
| Completed | Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique NCT02910934 | PATH | N/A |
| Completed | Proactive Community Case Management (Pro-CCM) in Rural Madagascar NCT05223933 | Institut Pasteur de Madagascar | N/A |
| Recruiting | Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human NCT02639299 | National Institute of Allergy and Infectious Diseases (NIAID) | — |
| Completed | Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis NCT02858817 | University Hospital Tuebingen | Phase 1 |
| Completed | Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2) NCT02932072 | University of Oxford | — |
| Completed | RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission NCT02878200 | London School of Hygiene and Tropical Medicine | N/A |
| Completed | Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea. NCT02859350 | Sanaria Inc. | Phase 1 |
| Completed | Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers NCT02963324 | University Hospital, Basel, Switzerland | Phase 1 |
| Completed | Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines A NCT02942277 | National Institute of Allergy and Infectious Diseases (NIAID) | Phase 1 |
| Completed | A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate NCT02927145 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria NCT03056391 | Menzies School of Health Research | Phase 3 |
| Completed | Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method NCT02996513 | Wageningen University | N/A |
| Completed | Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania NCT02909712 | London School of Hygiene and Tropical Medicine | Phase 2 |
| Completed | Prevention of Malaria in HIV-uninfected Pregnant Women and Infants NCT02793622 | University of California, San Francisco | Phase 3 |
| Withdrawn | Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia NCT02793414 | Menzies School of Health Research | — |
| Withdrawn | A Trial on Supervised Primaquine Use in Ethiopia NCT02793388 | Menzies School of Health Research | Phase 4 |
| Completed | Sequential Optimization of Dose and Schedule of PfSPZ Vaccine NCT02704533 | Sanaria Inc. | Phase 1 |
| Completed | A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant NCT02925403 | University of Oxford | Phase 1 / Phase 2 |
| Completed | A FIH Study to Investigate the Safety, Tolerability and PK of P218 NCT02885506 | Medicines for Malaria Venture | Phase 1 |
| Completed | Early Life Cohort in Papua Indonesia (ELIPI Study) NCT02793336 | Menzies School of Health Research | — |
| Completed | A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP NCT02905019 | University of Oxford | Phase 1 / Phase 2 |
| Completed | Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months NCT03035305 | Alliance for International Medical Action | N/A |
| Completed | Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living i NCT02687373 | Sanaria Inc. | Phase 1 / Phase 2 |
| Completed | Phase 2 Efficacy Study of Primaquine and Methylene Blue NCT02831023 | University of California, San Francisco | Phase 2 |
| Completed | Insecticide Resistance Management in Burkina Faso and Côte D'Ivoire NCT03074435 | Institut de Recherche pour le Developpement | Phase 3 |
| Unknown | Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children NCT02414399 | University of Washington | Phase 4 |
| Completed | Malaria Genetic Surveillance in Cambodia NCT03384472 | University of Oxford | — |
| Completed | Controlled Human Malaria Infection Model for Evaluation of Transmission-Blocking Interventions - Study 1 NCT02836002 | Radboud University Medical Center | Phase 1 / Phase 2 |
| Withdrawn | Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya NCT02294201 | University of Notre Dame | N/A |
| Withdrawn | Leiden University Medical Center Mini Donor Bank NCT02810613 | Leiden University Medical Center | — |
| Completed | Post-discharge Malaria Chemoprevention(PMC) Study NCT02671175 | Liverpool School of Tropical Medicine | Phase 3 |
| Completed | Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers NCT02788864 | Oxford University Clinical Research Unit, Vietnam | Phase 4 |
| Completed | MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B NCT02783833 | Medicines for Malaria Venture | Phase 1 / Phase 2 |
| Completed | Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A NCT02783820 | Medicines for Malaria Venture | Phase 1 |
| Completed | Child Follow-up Until 2 Years NCT02800109 | University of Oxford | — |
| Completed | Empirical ANtibiotic THErapy in Adults Hospitalised With Malaria NCT03224052 | Menzies School of Health Research | — |
| Unknown | Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA) NCT02739763 | University of Oxford | Phase 1 |
| Completed | Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot NCT02742285 | Thierry Buclin | Phase 4 |
| Completed | Cohort Event Monitoring in Sub Saharan Africa NCT02817919 | African Collaborating Centre for Pharmacovigilance | — |